JonesTrading Upgrades Deciphera Pharmaceuticals to Hold
JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Sell to Hold.
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
Benzinga’s Top Ratings Upgrades, Downgrades For January 4, 2023
Upgrades UBS upgraded the previous rating for Trane Technologies PLC (NYSE:TT) from Neutral to Buy. For the third…
SVB Leerink Maintains Outperform on Deciphera Pharmaceuticals, Raises Price Target to $28
SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $25 to $28.
Guggenheim Upgrades Deciphera Pharmaceuticals to Buy, Announces $22 Price Target
Guggenheim analyst Michael Schmidt upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Neutral to Buy and announces $22 price target.
Analyst Bullish On Theseus Pharma’s Platform For Gastric Cancer Therapies
Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22. Theseus’ discovery platform…
Deciphera Pharmaceuticals Q3 EPS $(0.55) Beats $(0.58) Estimate, Sales $35.97M Beat $33.15M Estimate
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.58) by 5.17 percent. This is a 59.85 percent increase over losses of $(1.37) per
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Earnings Outlook For Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Deciphera Pharmaceuticals will report an earnings per share (EPS) of $-0.58.
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…